Deans

Name:Xue-Feng Yu

Dean of Department of Endocrinology, TJH;
Professor of Medicine, TJH;
Board Member of the Chinese Society of Diabetes;
Board Member of the Chinese Society of Osteoporosis;
Board Member of the Endocrinology and Metabolism Branch of Chinese Physician Association;
Vice-Chairman of Endocrine Society of Hubei Province;
Vice-Chairman of Diabetes Society of Hubei Province;
Vice-Chairman of osteoporosis the Gerontological Society of Hubei Province, Bone Professional Committee;
Editorial Board Member of Journal of Internal Intensive Medicine;
Editorial Board Member of Drug Evaluation;
Editorial Board Member of Journal of Clinical Internal Medicine;
Editorial Board Member of Chinese Journal of Diabetes.

Educational Background

Postdoctoral, Department of Biology, Washington University in St. Louis, USA,2006;
Ph.D., University of Sheffield of UK, 1998;
M.S., Tongji Medical University, 1988;
B.S., Tongji Medical University, 1985.

Research

Diabetes, metabolic bone disease, endocrine system diseases.

Key Projects Involved

1. The regulatory mechanism and clinical significance of the expression of osteoclast precursors CXCR4 (National Natural Science Foundation of China, approval number: 30772207,2008-2010) , a total of 290,000 yuan fund (Project Leader);
2. Tongji Hospital Fund (8 thousands yuan): the role of Par-1b on insulin sensitivity and its potential mechanism (project leader);
3. National Basic Research Program of China (973 Program) of prevention and treatment of heart failure and malignant arrhythmia. basic research - heart failure, metabolism and apoptosis mechanism (No. 2007CB512004, 150 million yuan, project leader: Yang Shilin, Yu Xuefeng, Gang Yuan ; executive chief: Wang Daowen; 2007-2010) (2007);
4. Arachidonic acid metabolites Table oxidase CYP - EETs plays a role in the prevention of type 2 diabetes and insulin resistance and the mechanistic research (National Natural Science Foundation of China, 187 million yuan, project leader: Wang Daowen, Yu Xuefeng (2010 - 2012) (2010).

Honors & Awards

1.Yu X,New Investigator Award. Seventh International Conference on the Chemistry and Biology of Mineralized Tissues (Ponte Vedra Beach,Florida,USA, 2001).
2. Yu Xuefeng, the blood level changes of gonadotropin, calcitonin in the patients with diabetes. Received Outstanding Youth of Science and Technology, 1989 Tongji Medical University Paper Award; third prize of Hubei Province Natural Science Outstanding Paper Award (1990).
3. Jin Yan, Li Jianhua, Zhang Jianhua, Yu Xuefeng, Liu Pei Shen, Cui Wuren. The radioimmunoassay of serum calcitonin and its normal value. Research Achievement Award of Wuhan,1991.

Publication

1.Yu X, Scholler, Foget NT. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone. 1996 19(4): 339-45.(SCI included, impact factor 3.9)
2.Collin-Osdoby P, Yu X, Zheng H, Osdoby P. RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol Med. 2003; 80:153-66.
3. Yu X, Huang Y, Collin-Osdoby P, Osdoby P.Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res. 2003; 18(8):1404-18. (SCI included, impact factor 6.5)
4. Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity. Connect Tissue Res. 2003; 44 Suppl 1:79-84.( SCI included, impact factor 2.1)
5. Yu X, Huang Y, Collin-Osdoby P, Osdoby P.CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res. 2004; 19(12):2065-77. (SCI included, impact factor 6.5)
6. Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone.2005; 36(5):840-53. (SCI included, impact factor 3.9)
7. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates iNOS expression and NO production in developing osteoclasts: an autocrine negative feedback mechanism triggered by RANKL-induced IFN-β via NF-B  that restrains osteoclastogenesis and bone. J Biol Chem. 2006; 281(23):15809-20. (SCI, impact factor 5.8)
8. Song Yu, HE Ye Bing, Zhang Mu Xun, Yu Xuefeng. Department of neuroendocrine pancreatic tumors caused by ectopic ACTH syndrome. Endocrinology and Metabolism 2008; 24 (5) :576-577
9.Yu Xuefeng. Intensive glucose control in diabetic nephropathy status. Clinical Nephrology 2007; 7 (5) :212-213
10. Liu Peiwen, Yu Xuefeng. From the pathogenesis of type 2 diabetes diabetes treatment on the new strategy. Medicine and Philosophy (clinical decision-making forum) 2008; 29 (2) :10-13
11.Xie Junhui, Chen Xiaobin, Li Yujun, handsome Hongxia, Zhang Jianhua, Yu Xuefeng. And ? Stromal cell chemokine -1  type 2 diabetes and insulin resistance study. Huazhong University (Medical Edition) 2009; 38 (1) :113-115
12. Shao S, Fang Z, Yu X, Zhang M.. Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells. Biochem Biophys Res Commun. 2009 Jul 10;384(4):401-4.
13.Yu Jing, Liu Peiwen, Yu Xuefeng. 2004-2008 Wuhan clinical analysis of bone mineral density test results. China Health and Nutrition: Clinical Medicine Journal 2010; 19:9
14.Yu Jing, Liu Peiwen, Wangyuan Ying, Tao Yan, Yu Xuefeng. Wuhan 11 559 subjects calcaneus bone density test results. China osteoporosis and bone mineral Diseases 2010 Dec; 3 (4) :246-250

Translation
Yu Xuefeng. main translation. Metformin gold standard. Shanghai Science and Technology Press, 2009. 360,000 words.

Conference Abstracts
1.Yu X, Foged NT, Delaisse JM. Stimulators in osteoclastic motility upregulate urokinase plasminogen activator activity in osteoclasts. J Bone Miner Res. 1997; 12 (Suppl. 1): S262-S262 (Abstract) ( SCI ) 19th Annuanl Meeting of the American Siciety for Bone and Mineral Research
2.Yu X, Collin-Osdoby P, Osdoby P. Differential expression of chemokine receptors and chemokines during osteoclast development. J Bone Miner Res. 2000; 15 (Suppl. 1): S390-S390 SU241 (Abstract) ( SCI) 22nd Annuanl Meeting of the American Siciety for Bone and Mineral Research
3. Yu X, Collin-Osdoby P, Osdoby P. Chemokine receptor profiles during mouse osteoblast development. J Bone Miner Res. 2000; 15 (Suppl. 1): S275-S275 SA226 (Abstract) ( SCI) 22nd Annuanl Meeting of the American Siciety for Bone and Mineral Research
4. Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 (MMP-9) activity. J Bone Miner Res. 2001; 16 (Suppl. 1): S504-S504 (Abstract) ( SCI ) 23rd Annuanl Meeting of the American Siciety for Bone and Mineral Research
5. Yu X, Collin-Osdoby P, Huang Y, Osdoby P. MIP-1 alpha and RANTES inhibit osteoblast alkaline phosphatase (ALP) activity and stimulate matrix metalloproteinase-2 (MMP-2) activity as a function of upregulated expression of chemokine receptor CCR1 during osteoblast development. J Bone Miner Res. 2001; 16 (Suppl. 1): S370-S370 (Abstract) ( SCI) 23rd Annuanl Meeting of the American Siciety for Bone and Mineral Research
6. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. SDF-1 recruits osteoclast (OC) precursors via inducing MMP 9: A mechanism independent from MMP-9 induction during RANKL-mediated OC differentiation. J Bone Miner Res. 2002; 17 (Suppl. 1): S450-S450 M244(Abstract) ( SCI) 24th Annuanl Meeting of the American Siciety for Bone and Mineral Research
7.Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Mechanisms for inflammatory bone loss: Catabolic effects of chemokines MIP-1 alpha and RANTES via coordinated actions on osteoblasts and osteoclasts. J Bone Miner Res. 2002;17 (Suppl. 1): S427-S427  M140(Abstract) ( SCI) 24th Annuanl Meeting of the American Siciety for Bone and Mineral Research
8. Yu X, Huang Y, Collin-Osdoby P, Osdoby P.TGF?1 upregulates CXCR4 expression in osteoclasts(OC): a possible mechanism to enhance OC survival and bone resorption. J Bone Miner Res. 2002;17 (Suppl. 1): S234-S234  SU226(Abstract) ( SCI) 25th Annuanl Meeting of the American Siciety for Bone and Mineral Research
9. Yu X, Huang Y, Collin-Osdoby PA, Osdoby PA. Chemokines acting through CCR1 or CCR5 differentially promote osteoclast recruitment, RANKL development, and function. J Bone Miner Res. 2004; 19 (Suppl. 1): S413-S413. (Abstract) ( SCI ) 26th Annuanl Meeting of the American Siciety for Bone and Mineral Research
10.Yu X ,Collin-Osdoby PA, Osdoby PA. Chemokine recruitment of osteoclast precursors by SDF-1 is enhanced by TGF beta elevation of CXCR4 or suppressed by IFN-alpha inhibition of CXCR4. J Bone Miner Res. 2005; 20 (Suppl. 1): S147-S147. (Abstract) ( SCI ).27th Annuanl Meeting of the American Siciety for Bone and Mineral Research
11. Yu X ,Collin-Osdoby PA, Osdoby PA.IFNg inhibits SDF-1 pre-OC recruitment by downregulating basal and TGF-b induced CXCR4 Expression. J Bone Miner Res. 2005; 21 (Suppl. 1): SA260-SA260. (Abstract) ( SCI ) 27th Annuanl Meeting of the American Siciety for Bone and Mineral Research